Search
                    Carboplatin Treatment Options in Kansas
A collection of 205 research studies where Carboplatin is the interventional treatment. These studies are located in the Kansas, United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
            169 - 180 of 205
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
                                
            
            
        Withdrawn
                            
            
                The purpose of this study is to determine if EGFR status (positive or negative) by FISH can predict response to cetuximab therapy in NSCLC patients treated with carboplatin and paclitaxel             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/26/2015
            
            Locations: Local Institution, Wichita, Kansas         
        
        
            Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 120 years
            Trial Updated:
                10/23/2015
            
            Locations: Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas  +2 locations         
        
        
            Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
        
            
        
    
                
                                    Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
                                
            
            
        Completed
                            
            
                This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/28/2015
            
            Locations: Cancer Center of Kansas - Chanute, Chanute, Kansas  +6 locations         
        
        
            Conditions: Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
        
            
        
    
                
                                    Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
                                
            
            
        Terminated
                            
            
                The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/23/2015
            
            Locations: Cancer Center Of Kansas, Wichita, Kansas         
        
        
            Conditions: Non-small Cell Lung Cancer (NSCLC)
        
            
        
    
                
                                    A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
                                
            
            
        Terminated
                            
            
                A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/28/2014
            
            Locations: Not set, Hutchinson, Kansas  +1 locations         
        
        
            Conditions: Carcinoma, Non-Small Cell Lung
        
            
        
    
                
                                    Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                This randomized phase II trial is studying how well giving carboplatin and paclitaxel together with cetuximab and/or cixutumumab (IMC-A12) works in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and cixutumumab, can block tumor growth in different...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/19/2014
            
            Locations: Cancer Center of Kansas - Chanute, Chanute, Kansas  +18 locations         
        
        
            Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
        
            
        
    
                
                                    Combination Chemotherapy in Treating Children With Neuroblastoma
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma.
PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.             
        
        
    Gender:
                ALL
            Ages:
                20 years and below
            Trial Updated:
                07/31/2014
            
            Locations: Wesley Medical Center, Wichita, Kansas         
        
        
            Conditions: Neuroblastoma
        
            
        
    
                
                                    Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors.
PURPOSE: Phase III trial to compare the effectiveness of...  Read More             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                07/23/2014
            
            Locations: Wesley Medical Center, Wichita, Kansas         
        
        
            Conditions: Kidney Cancer
        
            
        
    
                
                                    Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
                                
            
            
        Terminated
                            
            
                Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/11/2013
            
            Locations: Pfizer Investigational Site, Kansas City, Kansas  +2 locations         
        
        
            Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/03/2013
            
            Locations: Bethany Medical Center, Kansas City, Kansas  +1 locations         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritonea...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                11/05/2013
            
            Locations: University of Kansas School of Medicine-Wichita, Wichita, Kansas         
        
        
            Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
        
            
        
    
                
                                    A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
                                
            
            
        Completed
                            
            
                The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative).
Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the poly (A...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                09/13/2013
            
            Locations: Research Site, Overland Park, Kansas  +1 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    169 - 180 of 205
            